NCT05345171Phase 3Active not recruiting

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

Study sponsor: Ultragenyx Pharmaceutical Inc · RARE

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-09Estimated

Enrollment · participants37Actual

Source updated2026-09-09Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-02 · 2 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~32 participants (planned)~~

+ After

37 participants (actual)

Check registry source

Posted 2026-02-17 · 2 fields changed

Completion date type changed

− Before

~~Actual~~

+ After

Estimated

Primary completion date changed

− Before

~~19 Feb 2025~~

+ After

Sep 2027

Check registry source